Table 3.

AEs occurring in >10% of patients by dose level (part 1 and part 2)

AE (preferred term)	25 mg (n = 2)		75 mg (n = 2)		100 mg (n = 8)		125 mg (n = 55)		150 mg (n = 6)		Overall (n = 73)		Related
													Overall (N = 73)		MM (n = 34)
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Nausea	0		1	50	3	37.5	18	32.7	4	66.7	26	35.6	17	23.3	7	20.6
Diarrhea	1	50	0		2	25	17	30.9	4	66.7	24	32.9	15	20.5	9	26.5
Dyspepsia	1	50	0		3	37.5	14	25.5	0		18	24.7	14	19.2	7	20.6
Fatigue	1	50	1	50	0		12	21.8	1	16.7	15	20.5	12	16.4	7	20.6
Anorexia	0		0		1	12.5	12	21.8	1	16.7	14	19.2	10	13.7	5	14.7
Gastrointestinal reflux	0		1	50	2	25	10	18.2	1	16.7	14	19.2	11	15.1	3	8.8
Vomiting	1	50	1	50	4	50	6	10.9	2	33.3	14	19.2	7	9.6	2	5.9
Anemia	0		1	50	3	37.5	7	12.7	0		11	15.1	2	2.7	2	5.9
Asthenia	0		0		1	12.5	8	14.5	1	16.7	10	13.7	2	2.7	0
Upper respiratory tract infection	0		0		2	25	7	12.7	1	16.7	10	13.7	0		0
Back pain	1	50	0		2	25	5	9.1	1	16.7	9	12.3	0		0
Insomnia	2	100	0		0		7	12.7	0		9	12.3	3	4.1	1	2.9
Rash	0		0		0		7	12.7	2	33.3	9	12.3	5	6.8	2	5.9
Constipation	0		0		1	12.5	7	12.7	0		8	11	0		0
Cough	0		0		3	37.5	5	9.1	0		8	11	1	1.4	0
Odynophagia	0		0		0		7	12.7	1	16.7	8	11	6	8.2	0
Headache	0		1	50	0		6	10.9	0		7	9.6	4	5.5	2	5.9
Neutropenia	1	50	0		2	25	3	5.5	1	16.7	7	9.6	5	6.8	2	5.9
Pyrexia	0		0		2	25	5	9.1	0		7	9.6	0		0